BioNTech vs Mabylon
BioNTech vs Mabylon, compared side by side on 16 data points: what each one does, how big it is, what it has raised, the tech running each site, and what users report. We score both out of 100 on traction, team and visibility: BioNTech is on 66/100 and Mabylon on 35/100.
Where each one leads
BioNTech
- our overall score: 66/100 against 35/100
- agent readiness: 40/100 against 30/100
- domain rating: 74/100 against 32/100
- funding raised: $975M against $35.8M
Mabylon
Leads on none of the measures we hold for both companies.
At a glance
| Measure | BioNTech | Mabylon |
|---|---|---|
| What it is | Global biopharmaceutical company pioneering mRNA-based immunotherapies and vaccines for cancer and infectious diseases. | Mabylon is a biotechnology company focused on developing innovative antibody-based therapies for infectious diseases and cancer. |
| Category | Biotechnology, Drug Discovery, Oncology, Immunotherapy | Biotech, MedTech, Drug Discovery, Antibody Therapeutics |
| Sells toBusiness model | B2B | B2B |
| Offering | Biotechnology | Platform |
| Founded | 2008 | Not published |
| Headquarters | Mainz, Germany | Geneva, Switzerland |
| Status | Active | Active |
Size, funding and growth
| Measure | BioNTech | Mabylon |
|---|---|---|
| Employees | 5,128 | Not published |
| Total funding | $975M | $35.8M |
| Latest round | Loan | Series A |
| LinkedIn followers | 295,812 | Not published |
StartupHub scores
Our own 0-100 ratings. They measure company strength and site quality, not which product suits you.
| Measure | BioNTech | Mabylon |
|---|---|---|
| StartupHub scoreOur 0-100 rating | 66/100 | 35/100 |
| Traction | 60/100 | 38/100 |
| Team | 70/100 | Not published |
| Search visibility | 35/100 | 2/100 |
| Quality | 78/100 | 45/100 |
| Agent readinessHow well an AI agent can read and act on the site | D (40/100) | F (30/100) |
| Domain ratingLink authority, 0-100 | 74/100 | 32/100 |
Technology
Detected on each public site, so it reflects the marketing stack as well as the product.
| Measure | BioNTech | Mabylon |
|---|---|---|
| Hosting | Azure | Self Managed |
| Frameworks | Not detected | Jquery, Bootstrap |
| Analytics | Google Tag Manager | Google Analytics 4 |
BioNTech vs Mabylon: common questions
Which is better, BioNTech or Mabylon?
On our 0-100 score BioNTech rates higher (66/100 against 35/100). The score weights traction, team, visibility and profile completeness, so it reflects company strength rather than which product suits you. We compare the two on 16 data points above: read the rows that match what you are buying for.
How do BioNTech and Mabylon compare on the numbers?
BioNTech leads on our overall score (66/100 against 35/100), agent readiness (40/100 against 30/100), domain rating (74/100 against 32/100), funding raised ($975M against $35.8M).
Read the full BioNTech review and pricing or the Mabylon review and pricing. You can also browse other BioNTech alternatives we track.